Sex, male (%)
Atopic dermatitis, n
Early wheezing, n
Age at first symptoms, years
Atopy status
negative skin prick tests, n
one positive prick test, n
more than one positive prick test, n
Parental atopy, n
Parental asthma, n
Longitudinal PFT characteristics
Duration of follow-up, years
ED Hospitalization frequency*
Number of PFT
Best sRaw reversibility in the past
Best FEV1 reversibility in the past
FEV1 slope, % per year
SD of FEV1 slope
|
5 (50)
5
3
0 [0; 3]
1
1
8
5
4
5.9 [5.0; 6.7]
0.000 [0.000; 0.071]
12 [12; 14]
56 [49; 65]
25 [16; 31]
+3.58 [+2.17; +4.52]
1.05 [0.83; 1.51]
|
135 (67)
89
88
1 [0; 4]
22
46
135
102
82
6.4 [5.6; 7.2]
0.066 [0.000; 0.200]
12 [11; 14]
55 [47; 62]
21 [15; 31]
-0.46 [-1.51; +0.45]
1.15 [0.85; 1.52]
|
59 (72)
38
38
0 [0; 3]
7
15
60
40
32
6.9 [6.1; 7.6]
0.071 [0.000; 0.166]
13 [11; 15]
53 [47; 61]
20 [14; 26]
-2.77 [-3.51; -2.11]
0.79 [0.64; 0.98]
|
0.3284
0.8767
0.6049
0.3989
0.8442
0.4897
0.4038
0.9752
0.9774
0.0098
0.5088
0.1240
0.5478
0.4196
ND
<0.0001
|
1,2<3
1,2>3
|
Spirometry at inclusion
Age, years
FEV1, L
FEV1, % predicted
FEV1, z-score
FVC, L
FVC, z-score
FEV1/FVC
FEV1/FVC, z-score
Obstructive defect, n (%)
|
9.3 [8.6; 11.9]
1.50 [1.42; 1.64]
84 [76; 88]
-1.40 [-1.98; -1.04]
2.09[1.92; 2.25]
-0.30 [-0.87; +0.28]
0.75 [0.71; 0.76]
-2.04 [-2.31; -1.65]
7 (70)
|
8.5 [8.2; 9.4]
1.61 [1.41; 1.76]
93 [83; 102]
-0.58 [-1.42; +0.15]
2.04 [1.79; 2.29]
+0.27 [-0.49; +0.99]
0.79 [0.73; 0.84]
-1.34 [-2.08; -0.76]
82 (40)
|
8.4 [8.2; 8.9]
1.62 [1.48; 1.78]
99 [90; 109]
-0.09 [-0.83; +0.74]
2.01 [1.83; 2.25]
+0.66 [-0.23; +1.23]
0.82 [0.77; 0.87]
-1.07 [-1.73; -0.28]
24 (29)
|
0.0187
0.2506
<0.0001
<0.0001
0.8246
0.0198
0.0020
0.0024
0.0240
|
1>2,3
1<2<3
1<2<3
1,2<3
1,2<3
1,2<3
1>3
|
Spirometry at last follow-up
FEV1, L
FEV1, % predicted
FEV1, z-score
FVC, L
FVC, z-score
FEV1/FVC
FEV1/FVC, z-score
Obstructive defect#, n (%)
Severe asthma, (%)§
|
3.82 [3.06; 4.28]
101 [95; 105]
+0.06 [-0.44; +0.40]
5.07 [3.59; 5.38]
+0.31 [-0.10; +0.63]
0.82 [0.81; 0.83]
-0.81 [-0.96; -0.64]
1 (10)
1 (10)
|
3.30 [2.77; 3.75]
91 [84; 100]
-0.76; -1.38; -0.01]
4.21 [3.54; 4.88]
+0.14 [-0.59; +0.86]
0.78 [0.73; 0.84]
-1.33 [-1.97; -0.75]
72 (35)
23 (11)
|
2.91 [2.67; 3.44]
82 [74; 88]
-1.46 [-2.14; -1.00]
4.00 [3.56; 4.47]
-0.49 [-1.11; +0.31]
0.74 [0.70; 0.80]
-1.88 [-2.35; -1.09]
46 (55)
21 (26)
|
0.0017
<0.0001
<0.0001
0.1465
0.0006
0.0003
0.0004
0.0008
0.0089
|
1,2>3
1>2>3
1>2>3
1,2>3
1,2>3
1,2>3
1,2<3
2<3
|
Clinical characteristics at last follow-up
Age, years
BMI, kg.m-2
SABA on demand, n
ICS, n
ICS dose, BED µg/day
LABA, n
Partially or uncontrolled last 3 months, n
Days, symptoms within last 3 months
Severe exacerbation$ within last 3 months, n
|
15.6 [15.3; 17.1]
21.1 [18.8; 23.4]
5
5
400 [325; 620]
3
4
0 [0; 5]
0
|
15.3 [14.6; 16.0]
20.2 [18.8; 22.0]
80
123
400 [200; 400]
114
94
1 [0; 7]
21
|
15.5 [14.9; 16.0]
18.9 [17.8; 20.7]
35
47
400 [200; 400]
46
25
0 [0; 3]
4
|
0.1262
0.0044
0.7290
0.7290
0.4971
0.2631
0.0492
0.0351
0.2010
|
1,2>3
2>3
2>3
|